New Code Signals Growing Market Acceptance for Side Branch Stents

DURHAM, N.C.--Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, announced that the German Institute for Medical Documentation and Information (DIMDI, Cologne) has revised the procedure code for the treatment of coronary bifurcations lesions, distinguishing dedicated side branch stent systems from conventional technique and providing for additional reimbursement for use of the Tryton side branch stent.

“This favorable reimbursement decision in Germany is evidence of continued market acceptance of the Tryton stent, which has now been used to treat more than 3,500 patients worldwide,” said Shawn P. McCarthy, president and CEO of Tryton Medical. “The expanded reimbursement validates our commitment to providing data supporting Tryton’s use in this problematic lesion subset.”

“Treating bifurcation lesions is a common, challenging problem for interventional cardiologists,” said Professor Jai-Wun Park of Asklepios Klinik Hamburg, Germany, who received the “Best Challenging Case Award” for a challenging patient case treated with the Tryton stent at the 23rd Annual Transcatheter Therapeutics (TCT) conference last month in San Francisco. “Tryton offers a solution with excellent efficacy and safety in a large and growing body of clinical data. In addition, and just as importantly, Tryton provides me with the confidence to easily treat these difficult lesions with the reliability I associate with more straightforward cases. It has become a mainstay in my clinical practice.”

Clinical data presented on more than 800 patients treated with the Tryton stent has demonstrated consistent target lesion revascularization rates of less than four percent at greater than six months follow up.

In addition, the Tryton stent is also being studied in the first and only randomized IDE clinical trial evaluating dedicated bifurcated stents. More than one-third of the 704 patients have been enrolled to date in the Tryton IDE study. The results of the trial will be submitted to the U.S. Food and Drug Administration (FDA) for approval to market the device in the United States.

Source: Tryton Medical, Inc.